Akebia Therapeutics
AKBA
166 hedge funds and large institutions have $448M invested in Akebia Therapeutics in 2018 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 73 increasing their positions, 24 reducing their positions, and 16 closing their positions.
231% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 16
217% more call options, than puts
Call options by funds: $4.16M | Put options by funds: $1.31M
204% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 24
28% more funds holding
Funds holding: 130 → 166 (+36)
24% more capital invested
Capital invested by funds: $360M → $448M (+$87.9M)
1.62% less ownership
Funds ownership: 71.53% → 69.91% (-1.6%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
+$192M |
| 2 |
ACM
Abrams Capital Management
Boston,
Massachusetts
|
+$35.5M |
| 3 |
BlackRock
New York
|
+$23.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18.4M |
| 5 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$9.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$15.7M |
| 2 |
Morgan Stanley
New York
|
-$6.68M |
| 3 |
PA
Perceptive Advisors
New York
|
-$5.84M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$4.37M |
| 5 |
First Manhattan
New York
|
-$4.23M |
AKBA Hedge Fund Activity: Q4 2018 in Review
166 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q4 2018, worth a combined $448M — up 24% from $360M a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new AKBA positions and 16 closed out — a net gain of 37 holders — while 73 added to existing stakes and 24 trimmed.
The largest buyer was Baupost Group, opening a new position worth an estimated $192M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $15.7M sold.
- 166 institutional investors held Akebia Therapeutics (AKBA) as of Q4 2018, up from 130 in Q3 2018.
- Funds reported $448M of Akebia Therapeutics stock for Q4 2018, up 24% quarter-over-quarter.
- 53 funds opened new Akebia Therapeutics positions in Q4 2018 and 16 closed out, a net change of +37 holders.
- The largest Akebia Therapeutics buyer in Q4 2018 was Baupost Group, an estimated $192M added.
- The largest Akebia Therapeutics seller in Q4 2018 was Renaissance Technologies, an estimated $15.7M sold.
Based on aggregated 13F filings for Q4 2018.